Wang P.-H.BOR-CHING SHEU2020-01-222020-01-222011https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052091853&doi=10.1016%2fj.jcma.2011.06.003&partnerID=40&md5=a3b094812f1b7a5f24ca33d6a3e83a90https://scholars.lib.ntu.edu.tw/handle/123456789/452504[SDGs]SDG3angiogenesis inhibitor; celecoxib; cytotoxic agent; paclitaxel; antiangiogenic activity; cancer immunotherapy; cancer recurrence; continuous infusion; editorial; female; human; melanoma; phase 2 clinical trial (topic); prognosis; vaginal melanoma; vulvectomy; Brain Neoplasms; Female; Humans; Melanoma; Neoplasm Recurrence, Local; Vaginal Neoplasmseditorial10.1016/j.jcma.2011.06.0032-s2.0-80052091853